chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Glucose tolerance test, Maternal exposure during pregnancy, Pregnancy test, Ultrasound foetal
Clinical narrative: prengancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (prengancy) in a 31-year-old female patient (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039K20A and 011L20A) for COVID-19 vaccination.     The patient's past medical history included Alcohol use (A glass of wine a night.) from 16-Oct-2009 to 12-Dec-2020. Concomitant products included PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] from 06-Jan-2020 to an unknown date for Prenatal care.   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 18-Nov-2020 and the estimated date of delivery was 25-Aug-2021. On 08-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (prengancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  eleventh week of the pregnancy.  On 03-Feb-2021, MATERNAL EXPOSURE DURING PREGNANCY (prengancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-Dec-2020, Pregnancy test: positive (Positive) Positive. On 06-Jan-2021, Ultrasound foetal: normal (normal) normal single fetus, normal NT. On 03-Feb-2021, Ultrasound foetal: normal (normal) normal single fetus, normal NT. On 18-Feb-2021, Ultrasound foetal: normal (normal) normal single fetus, normal NT. On 07-Apr-2021, Ultrasound foetal: normal (normal) normal single fetus, normal anatomy scan. On 18-May-2021, Glucose tolerance test: normal (normal) normal.         No treatment information was provided. Estimated date of conception was 29 Nov 2020.    Most recent FOLLOW-UP information incorporated above includes: On 18-May-2021: Updated pregnancy details LMP, PMH, Lab test. Added relevant information.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Headache, Lymphadenopathy, Pain
Clinical narrative: diarrhea; fever (101 to 103 F); soreness; vomiting; chills; swollen lymph nodes; headache; This spontaneous case was reported by a nurse and describes the occurrence of   in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 20-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to mod-2021-039953 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 23-Feb-2021: Follow up received on 23-Feb-2021, no new information was recorded On 11-Mar-2021: Patient details updated
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: diarrhea; fever (101 to 103 F); soreness; vomiting; chills; swollen lymph nodes; headache; This spontaneous case was reported by a nurse and describes the occurrence of   in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 20-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to mod-2021-039953 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 23-Feb-2021: Follow up received on 23-Feb-2021, no new information was recorded On 11-Mar-2021: Patient details updated
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: Nauseous; This spontaneous case was reported by a patient and describes the occurrence of NAUSEA (Nauseous) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Jan-2021, the patient experienced NAUSEA (Nauseous). At the time of the report, NAUSEA (Nauseous) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  The patient has not taken any medication for treatment, but plans to take something for the nausea.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pain, Injection site pruritus, Injection site urticaria, Injection site warmth
Clinical narrative: sore; hot; itching; rash; big red welt on her arm; red; This spontaneous case was reported by a patient and describes the occurrence of INJECTION SITE WARMTH (hot), INJECTION SITE PRURITUS (itching), RASH (rash), INJECTION SITE URTICARIA (big red welt on her arm) and INJECTION SITE ERYTHEMA (red) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Sulfonamide allergy (Allergy to sulfa).    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jan-2021, the patient experienced INJECTION SITE WARMTH (hot), INJECTION SITE PRURITUS (itching), RASH (rash), INJECTION SITE URTICARIA (big red welt on her arm) and INJECTION SITE ERYTHEMA (red). On 20-Jan-2021, the patient experienced INJECTION SITE PAIN (sore). At the time of the report, INJECTION SITE WARMTH (hot), INJECTION SITE PRURITUS (itching), RASH (rash), INJECTION SITE URTICARIA (big red welt on her arm), INJECTION SITE ERYTHEMA (red) and INJECTION SITE PAIN (sore) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment information was provided.    Most recent FOLLOW-UP information incorporated above includes: On 21-Jan-2021: Follow-up information included additional details regarding the patient, and the reported events. On 25-Jan-2021: Follow-up information included additional patient information.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: sore; hot; itching; rash; big red welt on her arm; red; This spontaneous case was reported by a patient and describes the occurrence of INJECTION SITE WARMTH (hot), INJECTION SITE PRURITUS (itching), RASH (rash), INJECTION SITE URTICARIA (big red welt on her arm) and INJECTION SITE ERYTHEMA (red) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Sulfonamide allergy (Allergy to sulfa).    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jan-2021, the patient experienced INJECTION SITE WARMTH (hot), INJECTION SITE PRURITUS (itching), RASH (rash), INJECTION SITE URTICARIA (big red welt on her arm) and INJECTION SITE ERYTHEMA (red). On 20-Jan-2021, the patient experienced INJECTION SITE PAIN (sore). At the time of the report, INJECTION SITE WARMTH (hot), INJECTION SITE PRURITUS (itching), RASH (rash), INJECTION SITE URTICARIA (big red welt on her arm), INJECTION SITE ERYTHEMA (red) and INJECTION SITE PAIN (sore) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment information was provided.    Most recent FOLLOW-UP information incorporated above includes: On 21-Jan-2021: Follow-up information included additional details regarding the patient, and the reported events. On 25-Jan-2021: Follow-up information included additional patient information.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during pregnancy, Pregnancy test, SARS-CoV-2 test, Ultrasound foetal
Clinical narrative: Pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) in a 33-year-old female patient (gravida 2, para 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     The patient's past medical history included Gestational diabetes (2019), Alcohol use (1 to 2 drinks per week) and Delivery (Pregnancy complication-Patient had gestational diabetes; Pregnancy outcome: Live, full-term birth) on May-2019. Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.    On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 26-Sep-2020 and the estimated date of delivery was 26-Jun-2021. On 09-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  fifteenth week of the pregnancy.  On 09-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 16-Oct-2020, Pregnancy test: positive (Positive) Positive. On 25-Oct-2020, SARS-CoV-2 test: positive (Positive) Positive. On 13-Nov-2020, Ultrasound foetal: normal (normal) Pregnancy Confirmed.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided by the reporter. Estimated date of conception 01 oct 2020.   Most recent FOLLOW-UP information incorporated above includes: On 14-Jun-2021: Follow-up received on 14-jun-2021 contains reporter's E-mail id.; Sender's Comments: .
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Glucose tolerance test, Maternal exposure during pregnancy, Pregnancy test, Ultrasound scan
Clinical narrative: pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (pregnancy) in a 28-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     The patient's past medical history included Alcohol use (binge, twice a week six drinks) from 01-Jan-2010 to 01-May-2014 and Drug abuse (daily for a year 30-90 mg daily) from 01-Jan-2013 to 01-May-2014. Concurrent medical conditions included Allergy to antibiotic. Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) from 01-May-2020 to an unknown date for Pregnancy.    On 21-Jan-2021 at 10:50 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 17-Jun-2020 and the estimated date of delivery was 05-Apr-2021. On 21-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  thirty-first week of the pregnancy. The delivery occurred on an unknown date, which was reported as Unknown. For neonate 1, The outcome was reported as Unknown. On 21-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (pregnancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 24-Jul-2020, Pregnancy test: positive (Positive) positive. On 30-Nov-2020, Ultrasound scan: normal (normal) Normal. On 07-Jan-2021, Glucose tolerance test: normal (normal) normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided. Patient estimated date of conception was on 13-jul-2020 patient under gone anotomy scan on 2-nov-2020 and 30-nov-2020 results are unknown
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Inappropriate schedule of product administration, SARS-CoV-2 test, Vaccination site pain
Clinical narrative: Headache; Hurting left arm at injection; Tired feeling; 2nd dose taken after 90 days as recommended; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose taken after 90 days as recommended), HEADACHE (Headache), VACCINATION SITE PAIN (Hurting left arm at injection) and FATIGUE (Tired feeling) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 007A21A and 011L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose taken after 90 days as recommended). On an unknown date, the patient experienced HEADACHE (Headache), VACCINATION SITE PAIN (Hurting left arm at injection) and FATIGUE (Tired feeling). On 09-Apr-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose taken after 90 days as recommended) had resolved. At the time of the report, HEADACHE (Headache), VACCINATION SITE PAIN (Hurting left arm at injection) and FATIGUE (Tired feeling) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 10-Jan-2021, SARS-CoV-2 test: (Positive) tested positive.         Concomitant product use was not provided by the reporter. Treatment information was not provided. .   This case was linked to MOD-2021-026867 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 14-Apr-2021: Patient demographics updated, 2nd dose information updated  and  events updated.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: sore arm; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (sore arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Jan-2021, the patient experienced VACCINATION SITE PAIN (sore arm). At the time of the report, VACCINATION SITE PAIN (sore arm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications were not provided. Treatment details were not provided   This case was linked to MOD-2021-010848 (Patient Link).; Sender's Comments: This case is under data review.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Myalgia, Pyrexia
Clinical narrative: Body aches; Chills; Fever (101 °F); This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Body aches), CHILLS (Chills) and PYREXIA (Fever (101 °F)) in a 28-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011J20A and 011J20A) for COVID-19 vaccination.     No Medical History information was reported.   On 23-Dec-2020 at 9:45 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Jan-2021 at 9:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 20-Jan-2021 at 7:00 PM, the patient experienced MYALGIA (Body aches), CHILLS (Chills) and PYREXIA (Fever (101 °F)). The patient was treated with ACETAMINOPHEN ongoing since an unknown date at an unspecified dose and frequency. On 21-Jan-2021, MYALGIA (Body aches), CHILLS (Chills) and PYREXIA (Fever (101 °F)) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 20-Jan-2021, Body temperature: 101 (High) 101 degrees Fahrenheit.         Concomitant product use was not provided by the reporter.  The patient's fever was reduced following treatment with Tylenol.  The patient endorsed having previously experienced the same symptoms when he had the flu.   Most recent FOLLOW-UP information incorporated above includes: On 15-Apr-2021: Follow-up information was received on 18 -Apr-2021 and was incorporated into the initial report.
Sex: U
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: hives approximately 5 hours later; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of URTICARIA (hives approximately 5 hours later) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced URTICARIA (hives approximately 5 hours later). At the time of the report, URTICARIA (hives approximately 5 hours later) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.  Concomitant product use was not provided by the reporter. No treatment information was provided.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site pruritus, Vaccination site warmth
Clinical narrative: Warm; itchy at injection site; Redness at injection site; tender at injection site/Painful at injection site; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION SITE WARMTH (Warm), VACCINATION SITE PRURITUS (itchy at injection site), VACCINATION SITE ERYTHEMA (Redness at injection site) and VACCINATION SITE PAIN (tender at injection site/Painful at injection site) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Dec-2020, the patient experienced VACCINATION SITE WARMTH (Warm), VACCINATION SITE PRURITUS (itchy at injection site), VACCINATION SITE ERYTHEMA (Redness at injection site) and VACCINATION SITE PAIN (tender at injection site/Painful at injection site). At the time of the report, VACCINATION SITE WARMTH (Warm), VACCINATION SITE PRURITUS (itchy at injection site), VACCINATION SITE ERYTHEMA (Redness at injection site) and VACCINATION SITE PAIN (tender at injection site/Painful at injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. No treatment information was provided.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema
Clinical narrative: arm is red at the injection site, It is red straight going down my arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (arm is red at the injection site, It is red straight going down my arm) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (arm is red at the injection site, It is red straight going down my arm). At the time of the report, VACCINATION SITE ERYTHEMA (arm is red at the injection site, It is red straight going down my arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.   This case was linked to MOD-2021-022253 (Parent-Child Link). This case was linked to MOD-2021-022253 (Patient Link).   See case MOD-2021-022253 for details regarding the child case.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Myalgia
Clinical narrative: Muscle ache; headache; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Muscle ache) and HEADACHE (headache) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported.). Concomitant products included IBUPROFEN for Headache and Myalgia.    On 31-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Dec-2020, the patient experienced MYALGIA (Muscle ache) and HEADACHE (headache). On 01-Jan-2021, MYALGIA (Muscle ache) and HEADACHE (headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment included Ibuprofen 400 milligrams.   Most recent FOLLOW-UP information incorporated above includes: On 14-Apr-2021: NNI
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Dermal filler overcorrection, Lip swelling, Oropharyngeal discomfort, Rash, Skin mass
Clinical narrative: the throat closes; lumps all over my body; fillers were bursting/fillers from 10 months or a year ago filled up; hives on her scalp; rash; hives; lips are swelling; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (hives), LIP SWELLING (lips are swelling), OROPHARYNGEAL DISCOMFORT (the throat closes), SKIN MASS (lumps all over my body) and DERMAL FILLER OVERCORRECTION (fillers were bursting/fillers from 10 months or a year ago filled up) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Genioplasty (Patient had chin implant from 25 years ago) and Breast implant user (Patient had silicone breast implants). Previously administered products included for Product used for unknown indication: Botox (Patient had Botox about 7 months ago) and Restylane. Concomitant products included STEROIDS, HYALURONIC ACID (JUVEDERM VOLUMA) and HYALURONIC ACID, LIDOCAINE (JUVEDERM ULTRA PLUS) for an unknown indication.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jan-2021, the patient experienced URTICARIA (hives) and RASH (rash). On 22-Jan-2021, the patient experienced OROPHARYNGEAL DISCOMFORT (the throat closes), SKIN MASS (lumps all over my body), DERMAL FILLER OVERCORRECTION (fillers were bursting/fillers from 10 months or a year ago filled up) and URTICARIA (hives on her scalp). On an unknown date, the patient experienced LIP SWELLING (lips are swelling). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency; METHYLPREDNISOLONE SODIUM SUCCINATE (SOLUMEDROL) (intravenous) at a dose of 125 milligram; METHYLPREDNISOLONE SODIUM SUCCINATE (SOLUMEDROL) (oral) at an unspecified dose and frequency; LORATADINE for Antihistamine therapy, at a dose of 10 milligram twice a day; FAMOTIDINE (PEPCID [FAMOTIDINE]) at an unspecified dose and frequency and EPINEPHRINE (EPIPEN) at an unspecified dose and frequency. At the time of the report, URTICARIA (hives), LIP SWELLING (lips are swelling), OROPHARYNGEAL DISCOMFORT (the throat closes), SKIN MASS (lumps all over my body), DERMAL FILLER OVERCORRECTION (fillers were bursting/fillers from 10 months or a year ago filled up), URTICARIA (hives on her scalp) and RASH (rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 23-Jan-2021: Additional events added.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: the throat closes; lumps all over my body; fillers were bursting/fillers from 10 months or a year ago filled up; hives on her scalp; rash; hives; lips are swelling; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (hives), LIP SWELLING (lips are swelling), OROPHARYNGEAL DISCOMFORT (the throat closes), SKIN MASS (lumps all over my body) and DERMAL FILLER OVERCORRECTION (fillers were bursting/fillers from 10 months or a year ago filled up) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Genioplasty (Patient had chin implant from 25 years ago) and Breast implant user (Patient had silicone breast implants). Previously administered products included for Product used for unknown indication: Botox (Patient had Botox about 7 months ago) and Restylane. Concomitant products included STEROIDS, HYALURONIC ACID (JUVEDERM VOLUMA) and HYALURONIC ACID, LIDOCAINE (JUVEDERM ULTRA PLUS) for an unknown indication.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jan-2021, the patient experienced URTICARIA (hives) and RASH (rash). On 22-Jan-2021, the patient experienced OROPHARYNGEAL DISCOMFORT (the throat closes), SKIN MASS (lumps all over my body), DERMAL FILLER OVERCORRECTION (fillers were bursting/fillers from 10 months or a year ago filled up) and URTICARIA (hives on her scalp). On an unknown date, the patient experienced LIP SWELLING (lips are swelling). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency; METHYLPREDNISOLONE SODIUM SUCCINATE (SOLUMEDROL) (intravenous) at a dose of 125 milligram; METHYLPREDNISOLONE SODIUM SUCCINATE (SOLUMEDROL) (oral) at an unspecified dose and frequency; LORATADINE for Antihistamine therapy, at a dose of 10 milligram twice a day; FAMOTIDINE (PEPCID [FAMOTIDINE]) at an unspecified dose and frequency and EPINEPHRINE (EPIPEN) at an unspecified dose and frequency. At the time of the report, URTICARIA (hives), LIP SWELLING (lips are swelling), OROPHARYNGEAL DISCOMFORT (the throat closes), SKIN MASS (lumps all over my body), DERMAL FILLER OVERCORRECTION (fillers were bursting/fillers from 10 months or a year ago filled up), URTICARIA (hives on her scalp) and RASH (rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 23-Jan-2021: Additional events added.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: soreness on the injection site; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE PAIN (soreness on the injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (soreness on the injection site). At the time of the report, VACCINATION SITE PAIN (soreness on the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient wanted to know if she could take Ibuprofen. Concomitant product use was not provided by the reporter. No treatment information was provided.
Age: 1.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy, Pyrexia
Clinical narrative: Nursing 12 month old developed swollen lymph nodes in his groin; Fever; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (Nursing 12 month old developed swollen lymph nodes in his groin) and PYREXIA (Fever) in a 12-month-old male infant exposed to mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L207) , while the mother received the product for COVID-19 vaccination.    MEDICAL HISTORY (Parent): Concurrent medical conditions included Maternal exposure during breast feeding.    MEDICAL HISTORY (Patient): The patient's past medical history included Exposure during breast feeding.    On 01-Feb-2021, the mother received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On 02-Feb-2021, the infant was diagnosed with LYMPHADENOPATHY (Nursing 12 month old developed swollen lymph nodes in his groin) and PYREXIA (Fever). The Infant was exposed to mRNA-1273 (Moderna COVID-19 Vaccine) during pregnancy.  The infant was treated with PARACETAMOL (TYLENOL) on 02-Feb-2021 for Fever, at an unspecified dose and frequency. On 04-Feb-2021, PYREXIA (Fever) had resolved. At the time of the report, LYMPHADENOPATHY (Nursing 12 month old developed swollen lymph nodes in his groin) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 02-Feb-2021, Pyrexia: 102.7 (High) Fever lasted for 12 hours.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Transmammary) was unknown.       Patient was given Tylenol twice within 12 hours& it got resolved on 04Feb2021. Patient was taken to pediatrician who ruled out flu & streptococcal  infection.  No concomitant medication information provided.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Blood test, Chest discomfort, Chills, Electrocardiogram
Clinical narrative: weakness; fatigue; headache; chills; chest pressure; This spontaneous case was reported by a consumer and describes the occurrence of  fatigue, asthenia, headache and chills in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Chest pressure.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient was treated with ASPIRIN [ACETYLSALICYLIC ACID] at an unspecified dose and frequency.      On 10 jan 2021, she experienced fatigue, weakness, and headache which have intermittently persisted until 19 Jan 2021. Additionally she notes her symptoms are not as strong in the morning, but there were 1 or 2 days in the beginning where the symptoms went away but then returned, but have been continuous for the past week. On 19 Jan 2021 her symptoms have become somewhat improved, but have not resolved. She has also has had some chills, but no fever, and is unsure of the timeline for her chills as they are not continuing on 19 Jan 2021.    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood test: normal (normal) Normal. On an unknown date, Electrocardiogram: normal (normal) Normal. On an unknown date, Vital signs measurement: normal (normal) Normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Vital signs measurement
Clinical narrative: weakness; fatigue; headache; chills; chest pressure; This spontaneous case was reported by a consumer and describes the occurrence of  fatigue, asthenia, headache and chills in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Chest pressure.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient was treated with ASPIRIN [ACETYLSALICYLIC ACID] at an unspecified dose and frequency.      On 10 jan 2021, she experienced fatigue, weakness, and headache which have intermittently persisted until 19 Jan 2021. Additionally she notes her symptoms are not as strong in the morning, but there were 1 or 2 days in the beginning where the symptoms went away but then returned, but have been continuous for the past week. On 19 Jan 2021 her symptoms have become somewhat improved, but have not resolved. She has also has had some chills, but no fever, and is unsure of the timeline for her chills as they are not continuing on 19 Jan 2021.    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood test: normal (normal) Normal. On an unknown date, Electrocardiogram: normal (normal) Normal. On an unknown date, Vital signs measurement: normal (normal) Normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Feeling hot, Headache, Heart rate increased
Clinical narrative: headache; felt super hot; weak; fast heart beat; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (felt super hot), ASTHENIA (weak), HEART RATE INCREASED (fast heart beat) and HEADACHE (headache) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included MULTIVITAMIN [VITAMINS NOS] for an unknown indication.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jan-2021, the patient experienced FEELING HOT (felt super hot), ASTHENIA (weak) and HEART RATE INCREASED (fast heart beat). On an unknown date, the patient experienced HEADACHE (headache). The patient was treated with ACETAMINOPHEN ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, FEELING HOT (felt super hot), ASTHENIA (weak), HEART RATE INCREASED (fast heart beat) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.  For mRNA-1273 (COVID 19 Vaccine Moderna) administered intramuscularly, the reporter did not provide any causality assessments.
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: Several itchy spots on her arm; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Several itchy spots on her arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Lymph node disorder (lymph node was on her left arm was removed several years ago).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRURITUS (Several itchy spots on her arm). At the time of the report, PRURITUS (Several itchy spots on her arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy
Clinical narrative: pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (pregnant) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced EXPOSURE DURING PREGNANCY (pregnant). At the time of the report, EXPOSURE DURING PREGNANCY (pregnant) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication information was provided.  No treatment medication information was given.
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy
Clinical narrative: Pregnant patient received second Moderna COVID-19 vaccine; This spontaneous prospective pregnancy case was reported by a health care professional and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant patient received second Moderna COVID-19 vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant patient received second Moderna COVID-19 vaccine). At the time of the report, EXPOSURE DURING PREGNANCY (Pregnant patient received second Moderna COVID-19 vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was provided.  Patient was pregnant and just received her second dose of the Moderna COVID-19 vaccine.  No treatment information was provided.; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this female patient. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site reaction
Clinical narrative: reaction a week later at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE REACTION (reaction a week later at the injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE REACTION (reaction a week later at the injection site). At the time of the report, VACCINATION SITE REACTION (reaction a week later at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.  No concomitant medication was provided.
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during delivery
Clinical narrative: Pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING DELIVERY (Pregnancy) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced MATERNAL EXPOSURE DURING DELIVERY (Pregnancy). At the time of the report, MATERNAL EXPOSURE DURING DELIVERY (Pregnancy) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment information provided by reporter.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Glucose tolerance test, Maternal exposure during pregnancy, Pregnancy test, Ultrasound foetal
Clinical narrative: Pregnant; This spontaneous prospective pregnancy case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) in a 29-year-old female patient (gravida 2) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028L20A and 025J20A) for COVID-19 vaccination.  The patient's past medical history included Sleep apnea (Stable) in 2015 and Narcolepsy (Stable) in 2015. Concurrent medical conditions included Hypertension since December 2020, Hypothyroidism (Stable) since December 2020, Migraine (Stable) in November 2020 and Heartburn since 2015. Concomitant products included FAMOTIDINE for Heartburn, ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for Hypertension, LEVOTHYROXINE for Hypothyroidism, MAGNESIUM OXIDE for Migraine, PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] for Pregnancy.  On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 29-Sep-2020 and the estimated date of delivery was 07-Jul-2021. On an unknown date, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the fourteenth week of the pregnancy. At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) had resolved.  DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Oct-2020, Pregnancy test: positive (Positive) Positive. In January 2021, Ultrasound foetal: inconclusive (Inconclusive) Inconclusive and inconclusive (Inconclusive) Inconclusive. In 2021, Glucose tolerance test: 105 (normal) 105.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.  No Treatment information was provided.  The patient's date of conception was 12-Oct-2020.  The patient had a miscarriage on 14-May-2020.  Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this female patient. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Injection site swelling, Pain
Clinical narrative: felt little pain/pain aching on the whole body; headache; injection site was swollen; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (felt little pain/pain aching on the whole body), HEADACHE (headache) and INJECTION SITE SWELLING (injection site was swollen) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Jan-2021, the patient experienced PAIN (felt little pain/pain aching on the whole body), HEADACHE (headache) and INJECTION SITE SWELLING (injection site was swollen). At the time of the report, PAIN (felt little pain/pain aching on the whole body), HEADACHE (headache) and INJECTION SITE SWELLING (injection site was swollen) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pruritus, Vaccination site swelling
Clinical narrative: Grape sized swelling near the injection Site; Grape sized swelling near the injection Site; Itchy sensation near the injection Site; Itchy sensation near the injection Site; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of the first episode of VACCINATION SITE PRURITUS (Itchy sensation near the injection Site), the second episode of VACCINATION SITE PRURITUS (Itchy sensation near the injection Site), the first episode of VACCINATION SITE SWELLING (Grape sized swelling near the injection Site) and the second episode of VACCINATION SITE SWELLING (Grape sized swelling near the injection Site) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced the first episode of VACCINATION SITE PRURITUS (Itchy sensation near the injection Site) and the second episode of VACCINATION SITE PRURITUS (Itchy sensation near the injection Site). On 17-Jan-2021, the patient experienced the first episode of VACCINATION SITE SWELLING (Grape sized swelling near the injection Site) and the second episode of VACCINATION SITE SWELLING (Grape sized swelling near the injection Site). At the time of the report, last episode of VACCINATION SITE PRURITUS (Itchy sensation near the injection Site) was resolving and last episode of VACCINATION SITE SWELLING (Grape sized swelling near the injection Site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. No treatment information was provided.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: tested positive; This spontaneous case was reported by an other health care professional and describes the occurrence of COVID-19 (tested positive) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COVID-19 (tested positive). At the time of the report, COVID-19 (tested positive) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.  No concomitant medication was provided.